[ad_1]
VIVA – With the new formulation, Her2-positive bad cancer treatment can now be shortened. Trastuzumab with a subcutaneous formulation only takes 2 to 5 minutes for treatment.
Trastuzumab was previously available only as an intravenous infusion. This method can take 30 to 90 minutes, which takes more time for the patient. But now with a new formulation, trastuzumab is administered to the patient by subcutaneous injection so that the required time becomes shorter.
According to medical staff of the Division of Hematology-Medical Oncology of Dharmais Cancer Hospital. dr. Nugroho Prayogo, SpPD-KHOM, the subcutaneous trusuzuman administration method, which is faster, not only beneficial for the patient, but also the service time of oncology nurses and hospital pharmacists.
Badan Pengawas Food and Drugs (BPOM) RI. Unfortunately, this treatment is still not included in BPJS funding
<img width = "100%" height = "auto" src = "https://static.viva.co.id/thumbs3/ 2018/03/27 / 5ab9b6a889408-hai-hati-ini-dia-gejala-kanker-payudara-yang-jarang-disadari_663_372.jpg "alt =" Breast Cancer. "At the moment, subcutaneous trastuzumab is still used by general patients and companies that represent 22% of patients in Dharmais. . For now still subject to enter into BPJS, "said the director of Dharmais Cancer Hospital, Dr. dr.H. Abdul Kadir, Ph.D., SpTHT-KL (K), MARS in a media education event at The Westin, Jakarta, Wednesday, July 12, 2018.
Although more time in the process of treatment, but this drug still has side effects to monitor.According to Nugroho, subcutaneous trastuzumab have side effects on the heart, but not permanent
we also monitor cardiac function, especially if the added chemotherapy drugs double the side effects of his heart. Should avoid the use of two drugs in a row, "said Nugroho.
Her2-positive bad cancer is the most aggressive type of bad cancer.All 22.8 percent of all women Indonesian, diagnosed with bad cancer, Her2-positive, 19659010]
[ad_2]
Source link
